The FDA warned more than 350 medical practices regarding unapproved versions of wrinkle fighter Botox as well as other drugs from Canada Drugs and its subsidiaries. The products could be unsafe, ineffective, counterfeit and contaminated, the FDA said. The FDA asked the practices to stop using the treatments in patients.
FDA warns 350 practices against unapproved versions of Botox
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Vice President of Finance||
Urban Health Plan, Inc.
|Director of Payor/Provider Contracting||
U.S. Medical Management